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1. Introduction {#s0005}
===============

Triclosan (TCS), a broad-spectrum antimicrobial chemical, has been widely used in personal-care products (toothpaste, mouthwash, antibacterial soap, hand sanitizer and cosmetics), clothing and plastics for \>40 years ([@bb0105]). The common commercial use of TCS has resulted in its ubiquitous presence in the environment, as well as its continuous exposure of various populations ([@bb0135]), including pregnant women ([@bb0135]; [@bb0070]; [@bb0035]; [@bb0040]; [@bb0165]; [@bb0235]; [@bb0230]). In our recent study, 98.2% of urine samples had detectable TCS (≥0.1 ng/mL) ([@bb0220]). Absorbed TCS in human body is mainly excreted via urine ([@bb0115]).

TCS is an endocrine disruptor chemical (EDC) with estrogenic/androgenic and thyroid hormone properties ([@bb0200]; [@bb0075]). Animal studies show that TCS exposure induced insulin resistance and metabolic disorder ([@bb0180]). In addition, maternal triclosan exposure was associated with increased plasma glucose, cholesterol, and triglycerides ([@bb0175]). There are increasing concerns of EDCs being risk factors for gestational diabetes mellitus (GDM), due to biological plausibility ([@bb0065]). The activation of estrogen receptors (ERs) may disrupt energy balance, fat and glucose metabolism ([@bb0185]; [@bb0010]). In addition, TCS was found to be associated with decreased free thyroxine (FT4) levels in women ([@bb0080]). The level of FT4 was inversely associated with incidence of GDM ([@bb0245]). However, no previous study examined the effect of maternal TCS exposure on GDM ([@bb0065]).

In the past two decades, the incidence of GDM has increased dramatically around world ([@bb0055]). The GDM incidence was found to be 18% on average in the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study, a large multinational cohort study ([@bb0190]). GDM affects about 18% of pregnancies in China, which has a profound impact on programming offspring metabolic disorders in local population ([@bb0240]; [@bb0225]). This study aimed to fill in the knowledge gap on whether TCS affects glucose metabolism and occurrence of GDM.

A few studies have examined the association between prenatal TCS and birth weight in industrialized countries where the exposures of TCS were relatively high and the results were inconsistent ([@bb0165]; [@bb0235]). An inverse but non-significant association was found between TCS and birthweight among male, but not female infants in a U.S. study ([@bb0235]). There were a few studies that examined the association between TCS and obesity ([@bb0120]; [@bb0125]). A recent study reported that urinary TCS level was associated with increased BMI in a U.S. adult population ([@bb0120]).

In this study, we aim to explore whether maternal urinary TCS level is associated with GDM and birth outcomes in male and female infants in China.

2. Data and methods {#s0010}
===================

2.1. Study population {#s0015}
---------------------

This birth cohort study was initiated at the International Peace Maternity and Child Hospital (IPMCH), a large tertiary maternity hospital in Shanghai, China, in 2012. Pregnant women were recruited between 2012 and 2013 when they were hospitalized for childbirth. Eligibility criteria included: 1) having routine prenatal care at the study hospitals; 2) singleton pregnancy; 3) planned to reside in Shanghai during the 2-year follow-up period; and 4) willing to participate in this study and sign the consent form. After obtaining a written informed consent, trained nurses conducted a face-to-face maternal interview using a standardized questionnaire and collected spot urine samples. Given that 1/5 to 4/5 of the oral dose of TCS was excreted to urine during the first 4 days after exposure, and the plasma half-life of TCS was 21 h ([@bb0195]), the urinary TCS concentration of the participants should represent their body burdens before hospital admission. The women usually delivered in the next day or two days after our investigation and sample collection. 71.6% of women delivered their infants by cesarean section (CS). After delivery, the study nurses reviewed maternal and infant medical records using a standardized abstraction form to obtain clinical data, including prenatal care, laboratory reports, pregnancy complications, labor and delivery course, and birth outcomes (infant sex, gestational age, birth weight, and birth length). All subjects gave an informed consent.

There were 680 eligible women who were enrolled. For this analysis, we excluded 60 enrolled women because they: did not collect urine sample (n = 38), had a medical complication (syphilitic) (n = 3), conceived by assisted reproductive technologies (ART) (n = 15), or had no urinary creatinine data (n = 1), urinary creatinine concentration \< 5 mg/dL (n = 2) ([@bb0020]) or \>300 mg/dL (n = 1) ([@bb0025]). This report included 620 women and their infants. 79 women had GDM. Power calculation was based on two-sample (GDM versus non-GDM) *t*-test. If we set significance level (alpha) = 0.05, to detect an effect size 0.35 (i.e. midway between small and medium), the power is 0.83.

This study was approved by the institutional review board of Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine and the International Peace Maternity and Child Hospital. All methods were performed in accordance with the relevant guidelines and regulations.

2.2. TCS exposure assessment {#s0020}
----------------------------

The urine samples were stored at −80 °C in polypropylene tubes until they were shipped on dry ice to the Xinhua Hospital, where they were stored at −80 °C before TCS analyses. TCS level was assayed with high-performance liquid chromatography--tandem mass spectrometry (HPLC--MS/MS) analytical method (Agilent 1290--6490, the United State) ([@bb0045]). Briefly, 4 mL urine sample was incubated with 2 mL of 1 mol/L ammonium acetate buffer solution (pH = 5.0) for hydrolyzation with 10 μL of β-glucuronidase/sulfatase (20,000 units/mL) at 37 °C overnight. Then the TCS was extracted and preconcentrated with solid phase extraction \[500 mg/3 mL, Supelclean ENVI-18, USA\]. After drying, the residue was dissolved in methanol. The solution was analyzed by LC-MS/MS. The limit of detection (LOD) was 0.1 ng/mL. The intra- and inter-day CV (coefficient of variation) for TCS were 1.4%--4.6%, and 3.0%--7.4% respectively. The solid phase extraction (SPE) recovery of TCS was 76.9%, and the accuracy (spike) recovery was 88.4%--110%, which indicated that the method is good and reliable. We prepared quality control (QC) samples from spiked pooled urine and analyzed QC samples along with standards, blanks and our urine samples. Creatinine concentrations of urine were measured with an automated chemistry analyzer (7100 Hitachi, Japan).

2.3. Outcomes {#s0025}
-------------

### 2.3.1. Main outcomes {#s0030}

#### 2.3.1.1. Definition of GDM {#s0035}

The screening for and diagnosis of GDM followed the recommendation of International Association of Diabetes and Pregnancy Study Groups (IADPSG) ([@bb0005]). Specifically, GDM was defined if a woman had any of the following plasma glucose values: (1) Fasting: ≥5.1 mmol/L; (2) 1 h: ≥10.0 mmol/L; and (3) 2 h: ≥8.5 mmol/L in the 75-g oral glucose tolerance test (OGTT) which was performed at 24--28 weeks of gestation ([@bb0005]). All the diagnoses of GDM were also verified by the obstetricians.

#### 2.3.1.2. Birthweight and Ponderal Index (PI) {#s0040}

Birthweight (g) and birth length (cm) were abstracted from the medical records. PI was calculated as: Birthweight (g) × 100 / Birth length ([@bb0070]) (cm^3^).

### 2.3.2. Secondary outcome {#s0045}

Prepregnancy BMI: Maternal prepregnancy BMI (kg/m ([@bb0135])) was calculated by prepregnancy weight obtained by self-report during questionnaire interview, and height abstracted from the medical records. We categorized BMI as underweight (\<18.5), normal (18.5--22.9), marginal overweight (23--24.9), and overweight (≥25.0) ([@bb0155]).

2.4. Definitions of major covariates {#s0050}
------------------------------------

Parity and infant sex were abstracted from the medical records. Maternal socio-demographic factors (including age and education level) and the information of smoking, passive smoking (husband smoking), and drinking during pregnancy were obtained by self-report. The women were asked, "Do you smoke cigarettes during pregnancy?" "If yes, when did you smoke (early-, mid-, or late-pregnancy)?" "How many cigarettes per day did you smoke?" They were also asked if her partner smoked (If yes, "When at home, how many cigarettes per day does he smoke in the room?").

Gestational age and preterm status: Gestational age was abstracted from the medical records. We determined the gestational age at delivery from maternal last menstrual period (LMP) and early ultrasound (\<20 weeks). If the gestational age estimated from the ultrasound differed by \>7 days from what was predicted by LMP, then we used the ultrasound assessment. For majority (97.4%) of the women, the gestational age was estimated based on LMP. Preterm was defined as gestational age \< 37 weeks, and term as ≥37 weeks.

3. Statistical analysis {#s0055}
=======================

The TCS levels were categorized into low, medium and high in tertiles. For TCS values below LOD of the assay, a value equal to the LOD divided by the square root of 2 was used for analysis. First, we compared maternal and infant characteristics by tertile of TCS, using ANOVA F-tests for continuous variables and *χ*^2^ tests for categorical data ([Table 1](#t0005){ref-type="table"}). Then, we used multinomial logistic regressions to evaluate the odds of prepregnancy BMI \< 18.5, 23--24.9 and ≥25 versus 18.5--22.9 according to prenatal TCS tertiles (eAppendix Tables A). We performed logistic regression to evaluate the association between prenatal TCS tertiles and GDM ([Table 2](#t0010){ref-type="table"}), and used linear regression models to evaluate the associations of TCS with maternal plasma glucose levels during 75 g--OGTT (fasting, at 1 h, at 2 h, respectively), and infant birthweight. The directed acyclic graph is shown at eAppendix Fig. A.Table 1Characteristics of study participants by maternal prenatal urinary triclosan (TCS) levels.Table 1TCS (ng/mL)p valueLowMediumHighn206207207Urinary TCS (ng/mL) Median (range)0.77 (\<LOD, 1.44)2.65 (1.47,4.99)13.34 (4.99, 95.20) log (TCS) (ng/mL)−0.47 ± 0.750.98 ± 0.352.77 ± 0.81\<0.001 log (TCS) (μg/g creatinine)0.48 ± 1.001.54 ± 0.783.41 ± 1.06\<0.001Maternal factors Age at childbirth (years)30.2 ± 3.230.4 ± 3.430.3 ± 3.50.77 Height (cm)162.5 ± 5.0162.1 ± 4.7162.1 ± 4.90.66 Prepregnancy weight (kg)54.6 ± 7.257.1 ± 9.056.4 ± 8.80.01 Prepregnancy BMI (kg/m^2^)20.68 ± 2.4821.72 ± 3.2221.45 ± 3.170.001Plasma glucose (mmol/L) during OGTT Fasting4.1 ± 0.54.2 ± 0.44.3 ± 0.40.02 1 h7.7 ± 1.67.8 ± 1.58.1 ± 1.90.21 2 h6.4 ± 1.36.5 ± 1.26.7 ± 1.60.21Length of gestation at time of OGTT (weeks)26.5 ± 2.527.0 ± 2.926.3 ± 2.40.08Education ≤High school14 (6.9)10 (4.8)11 (5.3)0.32 College163 (79.9)181 (87.4)170 (82.5) ≥Master degree27 (13.2)16 (7.7)25 (12.1)Household income (Chinese Yuan/year)0.22 \<50,0007(3.4)9(4.3)8(3.9) 50,000--100,00021(10.2)25(12.1)25(12.1) 100,000--200,00062(30.1)49(23.7)64(30.9) \>200,00056(27.2)66(31.9)40(19.3) Unknown60(29.1)58(28.0)70(33.8)Husband smoking during pregnancy51 (24.9)54 (26.6)46 (22.4)0.62Parity, nulliparous182 (88.3)177 (85.5)187 (90.3)0.31Prepregnancy BMI (kg/m^2^) categories \<18.529 (14.1)30 (14.5)34 (16.5)0.003 18.5--22.9144 (70.2)110 (53.1)116 (56.3) 23--24.922 (10.7)38 (18.4)30 (14.6) ≥2510 (4.9)29 (14.0)26 (12.6)GDM21 (10.2)21 (10.1)37 (17.9)0.03Hypertensive disorders of pregnancy None183(88.8)184(88.9)186(89.9)0.93 Chronic hypertension or gestational hypertension15(7.3)16(7.7)12(5.8) Preeclampsia8(3.9)7(3.4)9(4.3)Infant factors Gestational age (weeks)38.7 ± 1.038.9 ± 1.238.8 ± 1.00.19 Birthweight (g)3414.8 ± 407.33429.3 ± 399.43497.1 ± 412.00.09 Crown-heel length (cm)50.0 ± 0.850.1 ± 0.950.2 ± 1.20.11Ponderal Index (100 g/cm^3^)2.72 ± 0.242.72 ± 0.242.76 ± 0.240.29Sex, male114 (55.3)98 (47.3)110 (53.1)0.24Preterm birth3 (1.5)5 (2.4)0 (0.0)0.09[^1][^2]Table 2The association between maternal prenatal urinary TCS level (ng/mL) and GDM in 620 women, Shanghai, China.Table 2Case n (%)GDMUnadjusted OR (95% CI)Adjusted[c](#tf0015){ref-type="table-fn"} OR (95% CI)Urinary TCS Low21 (10.2%)1.001.00 Medium21 (10.1%)0.99 (0.53,1.88)0.78 (0.40,1.55) High37 (17.9%)1.92 (1.08,3.41)[b](#tf0010){ref-type="table-fn"}1.70 (0.92,3.13)[a](#tf0005){ref-type="table-fn"}  Trend testp~trend~ = .02p~trend~ = .05Linear log (TCS)1.20 (1.03,1.41)[b](#tf0010){ref-type="table-fn"}1.17 (0.99, 1.39)[a](#tf0005){ref-type="table-fn"}[^3][^4][^5]

For all regression models, we included natural logarithm of urinary creatinine and those known risk or protective factors of GDM or prepregnancy obesity (maternal age ([@bb0140]), education ([@bb0210]), passive smoking ([@bb0210]) and parity ([@bb0050])) and prepregnancy BMI categories. For models of birthweight measures as dependent variables ([Tables 4](#t0020){ref-type="table"}), we performed the models in male and female infants separately, and additionally included maternal height, prepregnancy BMI categories, GDM, and gestational age in Model to explore if the associations between TCS and birthweight outcomes go beyond the pathway through maternal obesity and GDM. The approach used for selection of covariates in the final models was to control the potential confounders (eAppendix Fig. A) and gain precision (e.g., the adjustment for maternal height and gestational age for birthweight as dependent variables) ([@bb0110]). All analyses were performed with SAS 9.1 software (SAS Institute, Cary, North Carolina). All reported p values were two-sided, and the level of statistical significance used was p \< .05.

4. Results {#s0060}
==========

4.1. Study population {#s0065}
---------------------

This study included 620 mother-infant pairs. 48.1% of infants were females. Mean age of the mothers at delivery was 30 (SD 3) years. 94.3% had a college education or above. 24.6% of the women reported exposure to passive smoking (husband smoking). Few women (n = 2) reported smoking, and 2.3% of women reported drinking during pregnancy. We detected TCS in 97.9% of women. 14.6% of women had a BMI of 23--24.9 kg/m^2^, and 10.4% was overweight with BMI ≥ 25 kg/m^2^. 12.7% had diagnosed GDM. The proportion of GDM was similar among women who had CS versus vaginal delivery (13.8% versus 10.2%, *χ*^2^ test, p = .29). No women had pre-pregnancy history of diabetes. Among the three TCS tertile groups, there were differences in maternal prepregnancy weight, prepregnancy BMI (both as continuous and categories), fasting glucose during OGTT, and rate of GDM occurrence ([Table 1](#t0005){ref-type="table"}). For example, the proportion of GDM was about 10% in both the lowest and the medium tertile of urinary TCS, but 17.9% in the highest tertile (*χ*^2^ test, p = .03). There were no associations between maternal urinary TCS and hypertensive disorders ([Table 1](#t0005){ref-type="table"}).

Few (1.3%) infants were born preterm. Mean gestational age was 38.8 (SD 1.1) weeks. 6 infants were born with birthweight \<2500 g, and 56 (9%) of infants were born with birthweight ≥4000 g.

4.2. TCS, prepregnancy BMI and GDM {#s0070}
----------------------------------

With adjustment for urinary creatinine, maternal age, education, passive smoking and parity, the odds of prepregnancy overweight (BMI ≥ 25 kg/m^2^) was 2.69-fold (95% CI: 1.23, 5.91) higher for women with high TCS (median 13.3 ng/mL) versus low TCS (median 0.77 ng/mL) (eAppendix Tables A, Model 3). Every unit increase of natural logarithm value of TCS (ng/mL) was associated with 1.19-fold (95% CI: 0.99, 1.43) higher odds of maternal prepregnancy overweight with adjustments for urinary creatinine and other covariates (eAppendix Tables A, Model 3).

For women with vs. without GDM, as shown in [Fig. 1](#f0005){ref-type="fig"}, the natural logarithm of TCS (ng/mL) was 0.41 (95% CI: 0.06, 0.76) higher (Mean ± SD: 1.45 ± 1.55 vs. 1.04 ± 1.47), and the natural logarithm of creatinine-adjusted TCS (μg/g creatinine) was 0.39 (95% CI: 0.02, 0.75) higher in women with GDM (Mean ± SD: 2.15 ± 1.67 vs. 1.76 ± 1.52); but there was no difference in natural logarithm of urinary creatinine concentration (mg/dL) (mean ± SD: 3.91 ± 0.71 vs. 3.89 ± 0.74).Fig. 1Mean (SE) urinary TCS (ng/mL), TCS (μg/g creatinine), and creatinine (mg/dL) in 79 women with GDM and 541 without GDM, Shanghai, China, 2012 to 2013.Fig. 1

As compared to those with low TCS, women with high TCS levels had higher risk of GDM (OR = 1.70; 95% CI: 0.92, 3.13, p~trend~ = .05) and a higher level of fasting plasma glucose (β = 0.10; 95% CI: 0.01, 0.20 mmol/L, p~trend~ = .04) with adjustment for urinary creatinine, maternal age, education, passive smoking, parity and prepregnancy BMI categories ([Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}). Every unit increase of natural logarithm value of TCS (ng/mL) was associated with 1.17-fold (95% CI: 0.99, 1.39) higher odds of GDM, and 0.09 mmol/L higher plasma glucose (95% CI: −0.01, 0.20) at 1 h, 0.07 mmol/L higher (95% CI: −0.01, 0.16) at 2 h in 75 g-OGTT, with adjustments for urinary creatinine, prepregnancy BMI categories and other covariates ([Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}), but these associations were not statistically significant.Table 3The association between maternal prenatal urinary TCS level (ng/mL) and maternal plasma glucose at fasting, 1 h, and 2 h during 75 g-OGTT in pregnant women, Shanghai, China.Table 3Plasma glucose level during 75 g-OGTT (mmol/L)FastingAt 1 hAt 2 hUnadjusted β (95% CI)Urinary TCS level Low (n = 150)Ref.Ref.Ref. Medium (n = 127)0.10 (−0.01,0.20)[a](#tf0020){ref-type="table-fn"}0.09 (−0.30,0.49)0.13 (−0.19,0.45) High (n = 138)0.14 (0.04,0.24)[c](#tf0030){ref-type="table-fn"}0.34 (−0.05,0.73)[a](#tf0020){ref-type="table-fn"}0.29 (−0.03,0.60)[a](#tf0020){ref-type="table-fn"}*Trend test*p~trend~ = 0.006p~trend~ = 0.09p~trend~ = 0.08Linear log (TCS)0.03 (0.003, 0.06)[b](#tf0025){ref-type="table-fn"}0.12 (0.02, 0.23)[b](#tf0025){ref-type="table-fn"}0.09 (0.005, 0.18)[b](#tf0025){ref-type="table-fn"}  Adjusted β (95% CI)[d](#tf0035){ref-type="table-fn"}Urinary TCS level Low (n = 150)Ref.Ref.Ref. Medium (n = 127)0.04 (−0.06,0.15)−0.05 (−0.45,0.34)0.06 (−0.27,0.39) High (n = 138)0.10 (0.01,0.20)[b](#tf0025){ref-type="table-fn"}0.25 (−0.12,0.63)0.22 (−0.10,0.54)*Trend test*p~trend~ = 0.04p~trend~ = 0.18p~trend~ = 0.17Linear log (TCS)0.02 (−0.008, 0.05)0.09 (−0.01, 0.20)[a](#tf0020){ref-type="table-fn"}0.07 (−0.01, 0.16)[a](#tf0020){ref-type="table-fn"}[^6][^7][^8][^9]

4.3. TCS and birth outcomes {#s0075}
---------------------------

For female infants, those born to mothers with high TCS had 122.8 (95% CI: 13.9, 231.6) grams higher birthweight and 0.07 (95% CI: 0.003, 0.13) higher Ponderal Index (100 g/cm^3^) than infants born to mothers with low TCS, with adjustment for urinary creatinine, prepregnancy BMI categories, the presence of GDM and other potential confounders ([Table 4](#t0020){ref-type="table"}, eAppendix Table B). For male infants, maternal TCS was not associated with infant birthweight or Ponderal Index. Sex and TCS effect modification test showed p ≤ .05 for both birthweight and Ponderal Index ([Table 4](#t0020){ref-type="table"}, eAppendix Tables B).Table 4The association between maternal urinary triclosan levels and birthweight in female and male infants.Table 4Mean ± SDInfant birthweight (g)Unadjusted β (95% CI)Adjusted β (95% CI)[d](#tf0055){ref-type="table-fn"}FemaleUrinary TCS (ng/mL) Low (n = 92)3300 ± 422Ref.Ref. Medium (n = 109)3398 ± 39097.9 (−12.9, 208.7)[a](#tf0040){ref-type="table-fn"}41.9 (−64.8148.5) High (n = 97)3471 ± 393170.2 (56.3, 284.1)[c](#tf0050){ref-type="table-fn"}122.8 (13.9231.6)[b](#tf0045){ref-type="table-fn"}Trend testp~trend~ = .003p~trend~ = .03Linear log (TCS)50.9 (18.8, 83.0)[c](#tf0050){ref-type="table-fn"}37.2 (6.9, 67.5)[b](#tf0045){ref-type="table-fn"}  MaleUrinary TCS (ng/mL) Low (n = 114)3507 ± 372Ref.Ref. Medium (n = 98)3464 ± 409−43.2 (−151.5, 65.1)−88.7 (−190.6, 13.3)[a](#tf0040){ref-type="table-fn"} High (n = 110)3521 ± 42813.4 (−91.7, 118.4)−2.0 (−98.5, 94.6)Trend testp~trend~ = .81p~trend~ = .99Linear log (TCS)6.1 (−22.2, 34.3)0.03 (−26.0, 26.1)p for effect modification[e](#tf0060){ref-type="table-fn"}.04.05[^10][^11][^12][^13][^14]

5. Discussion {#s0080}
=============

To our knowledge, this is the first study to examine the association between maternal TCS and GDM. We found that maternal urinary TCS was associated with higher risk of GDM in this Chinese urban population in a univariate analysis, but the association was not statistically significant when pre-pregnancy BMI was included in the models. This suggested that triclosan-GDM association may partially intermediated via BMI. In addition, prenatal TCS level was associated with higher birthweight and Ponderal Index in female, but not male infants, after adjusting for potential confounders.

In this study, the urinary TCS concentration of pregnant women was lower than their counterparts in most developed countries. The median TCS was 2.7 ng/mL in this study, lower than what was reported in pregnant women in U.S. (11--24.7 ng/mL) ([@bb0235]; [@bb0145]), Puerto Rico (26.2 ng/mL) ([@bb0135]), Canada (around 21.6 ng/mL) ([@bb0230]), Spain (6.1 ng/mL) ([@bb0040]) and in France (24.1--30 ng/mL) ([@bb0165]), but comparable to or higher than those in Norway (\<2.3 ng/mL) ([@bb0035]) and Denmark (1.21 ng/mL) ([@bb0070]).

The prevalence of GDM among our study participants is similar to the average level in China ([@bb0240]). A recent study reported that the prevalence of GDM was 18.9% in Chinese women ([@bb0225]). Similarly, the prevalence of GDM was high (12.7%) in this study, and we used criteria of IADPSG for GDM diagnosis ([@bb0005]). In another large-scale study of Chinese pregnant women population, the prevalence of GDM was 4.3% by applying American Diabetes Association (ADA) criteria for GDM diagnosis ([@bb0240]). If we used ADA criteria, the prevalence of GDM would be 2.4%. In addition, the prepregnancy BMI of women in this study (mean ± SD: 21.3 ± 3.0 kg/m^2^) is comparable to what was reported in Chinese non-pregnant women of similar age in Shanghai (BMI = 21.1, 95% CI 20.5--21.7 kg/m^2^) ([@bb0100]) and in our previous study (BMI: 21.8 ± 2.6 kg/m^2^) ([@bb0155]).

In this study, high tertile of TCS level was associated with higher risk of GDM and increased levels of plasma glucose at fasting during 75 g-OGTT. We also found that these associations attenuated with additional adjustment for prepregnancy BMI categories. We speculate that the association between TCS and GDM might be explained both by the effect of TCS on maternal overweight, and to a lesser extent, by its direct effect on insulin resistance and glucose intolerance.

The positive association between TCS and risk of GDM is biologically plausible. TCS have estrogenic properties, acting as either an agonist or anagonist to estrogen receptors ([@bb0200]; [@bb0075]). The activation of estrogen receptors can affect insulin resistance and glucose metabolism ([@bb0185]; [@bb0010]). ERα stimulates insulin synthesis, and ERβ participates in the regulation of insulin release ([@bb0030]). Insulin is the only hormone that able to decrease blood glucose ([@bb0030]). Secondly, the structure of TCS is similar to thyroxine (T4), and the negative association between TCS exposure level and free/or total T4 has been reported in both animal and human studies ([@bb0060]; [@bb0015]). Given that lower FT4 level was associated with higher risk of GDM ([@bb0245]), it is evident that higher TCS should be associated with increased risk of GDM. Thirdly, triclosan has recently been found to alter the expression of multiple microRNAs ([@bb0090]). The alteration of microRNA expression in placental trophoblast cells may predict the development of GDM ([@bb0065]). Also, TCS can be absorbed through ingestion ([@bb0195]), and via skin ([@bb0150]). We can\'t exclude the possibility that the broad-spectrum antibacterial properties of TCS has potential to impact gut microbiota ([@bb0160]). Numerous studies have indicated that gut microbial composition and richness is related to human metabolism ([@bb0205]).

Few studies have examined the association between TCS exposure and BMI, and the results were inconsistent ([@bb0120]; [@bb0125]). A recent study of U.S. population aged 20--85 years found that urinary TCS was non-linearly associated with higher BMI, where TCS exposure was relatively high (ranged from \<2.3 to 3620 ng/mL) ([@bb0120]). In this pregnant women population of relatively low TCS exposure (range: \<0.1 to 95.2 ng/mL), our study suggested that maternal TCS was associated with higher risk of maternal prepregnancy overweight and GDM. Still, future prospective studies are needed.

As for TCS and birthweight, there were a few studies of this topic, and our finding was gender-specific. We found a positive association between maternal TCS and birthweight in female infants and an inverse but non-significant association in male infants. This association cannot be entirely explained by the mediation effect of GDM. Due to lacking of related studies, the pathways that do not involve GDM are yet to be identified. We speculate that the androgenic or estrogenic activity of TCS ([@bb0075]) may contribute to the sex modification in the association between TCS and birthweight in this study. In addition, non-association in male infants could be explained by the endocrine disrupting effects of TCS on the placenta ([@bb0095]; [@bb0215]). TCS is a potential inhibitor of estrogen sulfonation ([@bb0095]). Thus, high TCS exposure may decrease placental supply of estrogen to fetus, in turn, impair fetal growth ([@bb0095]; [@bb0215]). Also, in consistence with the previous studies, TCS was not associated with gestational age in our study ([@bb0235]).

In this study, the rate of CS is high according to its national prevalence ([@bb0130]). This might be due to higher CS rate in tertiary hospitals ([@bb0130]; [@bb0085]). On the other hand, the social and cultural factors (for example, preference for a scheduled day) rather than medical reasons also lead to a higher CS rate in China ([@bb0085]).

The strength of this study is that we were able to collect multiple pre- and perinatal factors, as well as a wide range of anthropometric measures and lab test results, and reach accurate diagnosis of GDM. In addition, the diagnosis of GDM was verified by the obstetricians, thus it ruled out any potential preexisting diabetes that was not identified prior to this pregnancy.

Our study also had limitations. We had a one time measure of prenatal TCS concentration at late pregnancy. However, there were several studies evaluating intra-person correlation and reliability of TCS concentrations in repeated urine samples during pregnancy ([@bb0135]; [@bb0035]; [@bb0230]; [@bb0170]), one of which had similar median TCS concentration to ours with an intraclass correlation coefficient (ICC) of 0.49 ([@bb0035]). Another recent study also reported that the accuracy was 86.7% when using a single spot urine sample collected during or post-pregnancy to predict the woman\'s overall TCS concentration corresponding to low, medium, or high exposure level ([@bb0230]). Thus, a spot urine sample was still reasonably good for epidemiologic study to reflect overall TCS exposure during pregnancy ([@bb0135]; [@bb0035]; [@bb0230]; [@bb0170]). In addition, any misclassification of TCS exposure levels, if existed, was most likely to be non-differential and draw the association results toward the null. Second, we used creatinine to adjust for urine dilution, and creatinine output rises as pregnancy progresses. However, since the urine samples were collected at similar gestational age with a mean (SD) of 38.8 (1.1) weeks in this study, the influence of creatinine by gestational age on the results should be limited. The use of specific gravity adjustment can be considered in future studies. Thirdly, urinary TCS concentration is relatively low in this study population. Although eligible women were enrolled independent of their GDM status and birth outcomes, caution is needed in generalizing our findings to other populations. Finally, we did not measure other environmental chemicals that may also affect metabolism.

6. Conclusion {#s0085}
=============

We found that maternal TCS at environmental exposure level was associated with elevated risk of GDM, but the association did not reach the level of statistical significance. Our results support further prospective study on health effect of maternal TCS exposure in preconception and early pregnancy on mother and their children.
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[^1]: Data are presented as Mean ± SD and n (%). OGTT: oral glucose tolerance test; GDM: gestational diabetes mellitus.

[^2]: ANOVA F-test for continuous variables, chi-square test for categorical values.

[^3]: p \< .1.

[^4]: p \< .05.

[^5]: Covariates included: log (creatinine), maternal age, education, passive smoking, parity and prepregnancy BMI categories (\<18.5, 18.5--22.9, 23--24.9, ≥25 kg/m^2^).

[^6]: p \< .1.

[^7]: p \< .05.

[^8]: p \< .01.

[^9]: Covariates included: log (creatinine), maternal age, education, passive smoking, parity and prepregnancy BMI categories: \<18.5, 18.5--22.9, 23--24.9, ≥25 kg/m^2^.

[^10]: p \< .1.

[^11]: p \< .05.

[^12]: p \< .01.

[^13]: Covariates included: log (creatinine), maternal age, height, prepregnancy BMI categories, GDM, education, passive smoking, parity and gestational age.

[^14]: p value for effect modification estimated in the models with sex (male, female), log (TCS) (linear term) and interaction of the two.
